Blontuvetmab

• CAT Number: I042154
• CAS Number: 1608112-78-2
• Purity: ≥95%

Blontuvetmab (Cat No.: I042154) is an investigational antibody-drug conjugate (ADC) designed to selectively target tumor-associated antigens, delivering cytotoxic payloads directly to cancer cells while minimizing damage to healthy tissue. As a targeted therapy, it combines a monoclonal antibody with a potent anti-cancer drug via a stable linker, allowing internalization and controlled drug release. Blontuvetmab is being explored for use in solid tumors and hematologic malignancies, offering a precision medicine approach that enhances efficacy and reduces systemic toxicity in oncology treatments.

Reference

[1]. Mizuno T, et, al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci Rep. 2020 Jul 10;10(1):11476.
[Content Brief]